A recent Experian Perceptions of AI Report that polled more than 200 decision-makers at leading financial institutions on ...

In July 2025, a class 2 resubmission of tab-cel’s BLA was initiated by Atara Biotherapeutics, developer and sponsor of ...

Beam Therapeutics jumps 22% after outlining 2026 pipeline goals, including accelerated approval plans for BEAM-302 and a ...

Genetic testing showed that childhood cancer survivors aged faster biologically, regardless of the treatment they received as ...

Manchester President Stacy Young discusses the university's Degree in 3 accelerated bachelor's degree program.

In high-intensity laser–matter interactions, including laser-induced particle acceleration, physicists generally want to work ...

Dr. Wagle says that artificial fats can get incorporated into brain cell membranes, changing their structure and making it ...

At Stanford, a treatment that aims magnetic pulses at the brain is showing results for people with treatment-resistant depression. It’s called SAINT, and here’s how it works.

The MajesTEC-9 trial showed a 40% reduced risk of death and a 71% reduced risk of disease progression or death with ...

Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Jan. 12, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – The oncology landscape is ...

The BLA was resubmitted in 2025, after Atara and the FDA aligned on the criteria and addressed the initial CRL conditions.